Abu Dhabi receives first global shipment of new AstraZeneca “Evusheld”

Abu Dhabi received the first global shipment of AstraZeneca’s Evusheld, long-acting antibody medication, after gaining Emergency Use Authorization (EUA) from the UAE’s Ministry of Health and Prevention. The long-acting antibody medication is designed to prevent severe infection and death amongst immunocompromised patients.
This medication will be in addition to the existing COVID19 medications that are already available within Abu Dhabi and the UAE to ensure the continuity of world-class care in the country.
Under the leadership of the Department of Health – Abu Dhabi (DoH), the first doses of Evusheld have arrived in Abu Dhabi on December 20th following a collaboration of key partners including Rafed, the UAE’S Primary Group Purchasing Organization and the procurement arm of the UAE, along with Etihad Cargo, the national cargo carrier of the Emirate of Abu Dhabi, in addition to AstraZeneca, the British-Swedish multinational pharmaceutical and biotechnology company, and Abu Dhabi Airports Company (ADAC). The breakthrough medication will be stored at Rafed’s Distribution Centre, the region’s largest cold-chain storage facility, and then distributed from there to various destinations.